Low-dose omega-3 intake does not raise atrial fibrillation risk, study finds
A new meta-analysis led by researchers from the Fatty Acid Research Institute (FARI) provides the clearest picture to date of the relationship between omega-3 fatty acid supplementation and atrial fibrillation (AF), helping resolve years of confusion generated by earlier reports.
A new meta-analysis conducted by researchers from the Fatty Acid Research Institute found that low-dose omega-3 fatty acid supplementation does not increase the risk of atrial fibrillation (AF) in individuals. The study, led by Dr. Nada Abuknesha, analyzed data from 35 randomized controlled trials involving 114,592 participants.
Previous studies suggested a potential link between omega-3 supplements and AF, but this new analysis included more comprehensive data and a wider range of trials. The research showed that only high-dose omega-3 therapy (1,500 mg/day or higher) used in patients with established cardiovascular disease was associated with a modestly increased AF risk of 0.8%.
The study's authors emphasized that low-dose omega-3 supplements, typically taken for general health and cardiovascular wellness, pose no meaningful increase in AF risk. They highlighted that the decision to take or discontinue omega-3 supplements should be made in consultation with a healthcare provider, as higher prescription-level doses in patients with established cardiovascular disease may pose a slightly higher risk, albeit still outweighed by the significant cardiovascular benefits demonstrated in major clinical trials.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
